Products - Prostate cancer | Topic | NICE

Showing 12 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [ID6452]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 September 2025
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 October 2025
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 November 2025
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 September 2026
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
Status:
In development
Programme:
Medical technologies guidance
Expected publication date:
TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC